CJC-1295 (no DAC)

Buy Cjc 1295 No Dac Research and Mechanism

Buy cjc 1295 no dac for laboratory research into growth hormone-releasing hormone signalling pathways. CJC-1295 without DAC, also known as Modified GRF (1-29) or Mod GRF 1-29, is a tetrasubstituted analog of the first 29 amino acids of human GHRH. According to comparative research data from HonestPeptide, the no-DAC variant lacks the drug affinity complex that enables albumin binding, resulting in a much shorter half-life of approximately 30 minutes compared to the DAC variant’s 5.8 to 8.1 days.citeweb_search:22#0 This pharmacokinetic profile makes cjc 1295 no dac a tool for studying pulsatile GH release patterns that more closely mimic endogenous GHRH physiology.

Research published in Palmetto Peptides indicates that cjc 1295 no dac activates the GHRH receptor on pituitary somatotroph cells without extended albumin binding, producing shorter, more pronounced GH spikes rather than sustained elevation.citeweb_search:22#1 The core sequence responsible for receptor binding is identical to the DAC variant; the difference is purely pharmacokinetic. It is critical to emphasise that cjc 1295 no dac is not approved by the TGA for human use. It is sold strictly for in vitro and laboratory research use only.

Cjc 1295 Dac or No Dac Research Comparison

Cjc 1295 Dac vs No Dac Mechanism

According to technical comparison data, cjc 1295 dac vs no dac differ fundamentally in duration of action. CJC-1295 with DAC incorporates a maleimide-lysine drug affinity complex that covalently binds cysteine-34 on serum albumin, creating a slow-release reservoir with a half-life of 7 to 10 days.citeweb_search:22#5 CJC-1295 no dac lacks this modification, clearing within 30 minutes to 1 hour and producing acute, pulsatile GH responses.citeweb_search:22#5web_search:22#7

For research applications, cjc 1295 dac or no dac selection depends on experimental design. The DAC variant is preferred for chronic exposure studies, sustained GH axis activation, and long-term IGF-1 maintenance. The no-DAC variant is preferred for acute response studies, pulsatile secretion modelling, and combination protocols with GH secretagogues where precise temporal control is required.citeweb_search:22#1web_search:22#5

Cjc 1295 No Dac Ipamorelin Blend Research

Researchers frequently investigate cjc 1295 no dac ipamorelin combinations because the two compounds act through complementary mechanisms. CJC-1295 no dac activates the GHRH receptor to stimulate endogenous GH release, while ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) in the pituitary. According to research protocol data, this dual-receptor approach produces additive or synergistic GH elevation while maintaining more physiological pulse patterns than either compound alone.citeweb_search:22#0

The cjc-1295 no dac+ipamorelin blend is commonly studied for acute GH pulse amplification research. The no-DAC variant’s short half-life allows multiple daily administration points that align with natural GH pulsatility, while ipamorelin provides additional secretagogue drive without cortisol or prolactin elevation. For researchers studying GH axis responsiveness, the combination offers a more complex signalling model than single-agent protocols.

Cjc-1295 No Dac Ipamorelin Dosage Per Day

For laboratory research, cjc-1295 no dac ipamorelin dosage per day protocols vary by study design. Typical reference ranges for cjc 1295 no dac are 100 to 300 micrograms per administration, with 2 to 3 daily doses timed to model physiological pulsatility. Ipamorelin is typically studied at 100 to 200 micrograms per dose, administered concurrently or offset by 30 to 60 minutes. These protocols are for research reference only and must be calibrated to specific assay requirements. All dosing parameters are for laboratory research use only.

Cjc 1295 No Dac Dosage and Reconstitution

Cjc 1295 No Dac Dose for Research Protocols

For laboratory research, cjc 1295 no dac is typically supplied as a 2mg lyophilised powder. According to research protocol references, typical laboratory dosing ranges from 100 to 300 micrograms per administration in preclinical models, with 2 to 3 daily doses to model pulsatile GH secretion.citeweb_search:22#1 For in vitro applications, working concentrations of 10 to 100 nanomolar are common reference points for studying GHRH receptor signalling and pituitary cell responses. Gently swirl the vial until fully dissolved. Do not shake vigorously. Allow the solution to settle at room temperature before aliquoting.

Reconstitution Guide

Remove the vial from freezer storage and allow it to equilibrate to room temperature for 15 to 20 minutes. Draw 1.0 to 2.0 mL of bacteriostatic water into a sterile syringe and inject slowly down the inner vial wall to minimise foaming. Gently swirl until fully dissolved. Label with the reconstitution date and store at 2 to 8 degrees C protected from light. Use within 14 to 21 days. Do not freeze reconstituted solution.

How Cjc 1295 No Dac Compares to Other Research Compounds

Cjc 1295 No Dac vs Cjc 1295 Dac

CJC-1295 DAC is the albumin-binding variant with a half-life of 5.8 to 8.1 days, producing sustained GH and IGF-1 elevation. Cjc 1295 no dac clears within 30 minutes, producing acute, pulsatile GH spikes. CJC-1295 DAC is preferred for chronic exposure and long-term axis activation studies. Cjc 1295 no dac is preferred for pulsatile modelling, acute response research, and combination studies with secretagogues. The choice depends on whether the research question requires sustained or pulsatile GH signalling.

Cjc 1295 No Dac vs Sermorelin

Sermorelin is a 29-amino-acid GHRH analog comprising the active fragment of native GHRH. Cjc 1295 no dac is a tetrasubstituted modified GRF (1-29) with enhanced enzymatic stability. Both produce short-acting GHRH receptor activation, but cjc 1295 no dac has greater resistance to DPP-IV degradation due to amino acid substitutions. Sermorelin is an older research tool with more clinical literature; cjc 1295 no dac is a newer analog with improved pharmacokinetic stability for laboratory applications.

Cjc 1295 No Dac vs Ipamorelin

Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release through a different receptor pathway than GHRH. Cjc 1295 no dac activates the GHRH receptor; ipamorelin activates the GHS-R1a receptor. When studied together, they produce additive GH elevation through dual-receptor stimulation.